Infant Bacterial Therapeutics AB is a clinical stage pharmaceutical company, which engages in the development of drugs for the treatment of rare diseases affecting premature infants. The company is headquartered in Stockholm, Stockholm and currently employs 10 full-time employees. The company went IPO on 2016-03-29. The firm develops drugs that meet the needs of the premature infant. The Company’s focus is on clinical development of IBP-9414, a drug candidate containing Lactobacillus reuteri, in the prevention of necrotizing enterocolitis (NEC), a fatal disease that affects premature infants.
